ArticleLower urinary tract symptoms2019

Three-year safety, efficacy and persistence data following the daily use of mirabegron for overactive bladder in the clinical setting: A Japanese post-marketing surveillance study.

Daisuke Kato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.